Abstract:OBJECTIVE:We analyzed data of lupus nephritis (LN) patients to find parameters that can predict remission. METHODS:Sixty-four LN patients who were diagnosed with class III, IV, V or V + III/IV by renal biopsy and were followed up for more than six months in our center were enrolled retrospectively. Receiver operating characteristic curves were used to test the predictive values of urinary protein-to-creatinine ratio (UPCR), serum albumin and complement C3 at the first, second and third months as predictors for remission at the sixth month. RESULTS:The patients' renal pathologies were class III (five cases), class IV (33 cases), class V (nine cases) and class V + III/IV (17 cases). All patients received standard immunosuppressive therapy. Forty-six (71.9%) patients (grouped as the remission group) achieved remission at the end of the sixth month, including 23 complete remissions and 23 partial remissions. The other 18 patients were grouped as the no-remission group. There were no significant differences in clinical data, proportion of immunosuppressive therapy or renal pathological characteristics between the remission group and no-remission group at baseline, except the serum urea nitrogen of the remission group was lower than in the no-remission group. The UPCR were significantly lower in the remission group than in the no-remission group at months 1, 2, 3 and 6, respectively, while the serum albumin was significantly higher in the remission group than in the no-remission group at months 3 and 6, respectively. There were no significant differences in serum creatinine between the remission group and no-remission group, except at month 1. The C3 levels were higher in the remission group than in the no-remission group at months 1, 2 and 3, respectively. The areas under the curve (AUC) of the change percentage of UPCR at month 3 and the serum albumin at month 3 were the most significant (AUC 0.778, p = 0.002; AUC 0.773, p = 0.001, respectively). The cutoff value of the change percentage of UPCR at month 3 was 59%. The cutoff value of serum albumin at month 3 was 32.9g/l. CONCLUSION:The change percentage of UPCR ≥59% and the serum albumin ≥32.9 g/l at the third month were valuable for predicting remission at the sixth month in LN. Because of the small-size and retrospective nature, this study needs to be validated.

Serum antineutrophil cytoplasmic antibody positivity at the time of renal biopsy is associated with disease activity of lupus nephritis

Early-stage predictors for treatment responses in patients with active lupus nephritis.

Treatment and Clinicopathological Characteristics of Lupus Nephritis with Anti-Neutrophil Cytoplasmic Antibody Positivity: a Case–control Study

Antineutrophil Cytoplasmic Autoantibodies (ANCA) and Their Target Antigens in Chinese Patients with Lupus Nephritis

Clinical features and outcomes of patients with antineutrophil cytoplasmic antibody-positive systemic lupus erythematosus

The uncertain correlation of ANCAs in patients with lupus nephritis and crescents, an experience from Chinese centers

Clinical Significance of Serum ANCA in Patients with Systemic Lupus Erythematosus

Monocyte Chemotactic Protein-1, Fractalkine, and Receptor for Advanced Glycation End Products in Different Pathological Types of Lupus Nephritis and Their Value in Different Treatment Prognoses.

Autoantibodies against monomeric C-reactive protein in sera from patients with lupus nephritis are associated with disease activity and renal tubulointerstitial lesions.

Association Analysis Etween Anti-nucleosome Antibodies: with Clinical Features and Disease Activity in Systemic Lupus Erythematosus of Chinese Han

Analysis of Immunity Index and Immunopathogenesis Pattern of Lupus Nephritis Patients

Serum Levels and Renal Deposition of C1q Complement Component and Its Antibodies Reflect Disease Activity of Lupus Nephritis

Characteristics and Renal Survival of Patients with Lupus Nephritis with Glomerular Immunoglobulin G4 Deposition: a Single-Centre Retrospective Analysis.

The study of the association of anti-C1q antibody with disease activity and lupus nephritis in SLE patients

Urinary levels of ceruloplasmin and monocyte chemoattractant protein-1 correlate with extra-capillary proliferation and chronic damage in patients with lupus nephritis

The Impact of Serum Anti-neutrophil Cytoplasmic Antibody on Clinical Characteristics and Outcomes in Pediatric-Onset Systemic Lupus Erythematosus Patients

Serum A08 C1 Q Antibodies Are Associated with Disease Activity and Prognosis in Chinese Patients with Lupus Nephritis

Association of urine autoantibodies with disease activity in systemic lupus erythematosus

Clinicopathological Features and Outcomes of IgA Nephropathy with Serum Antineutrophil Cytoplasmic Autoantibody Positivity

Noninvasive biomarkers for lupus nephritis

Role of Anti-C1q Antibodies as Indicator of Renal Activity in Systemic Lupus Erythematosus